Biological Immunology

Remicade

Payments companies reported to CMS as associated with Remicade. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$813Kassociated payments (2023-2025)

12,342clinicians with associated payments

4companies reporting

By year

2023 $654K

2024 $48K

2025 $111K

Payments reported as associated with Remicade, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $219K

Dermatology $100K

Pediatric Gastroenterology $97K

Physician Assistant $96K

Family $65K

Rheumatology $37K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Remicade

These are the largest totals companies reported as associated with Remicade. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
David Faleck	New York, NY	Gastroenterology (Internal Medicine)	$16,050.00
Jeffrey Hyams	Hartford, CT	Pediatric Gastroenterology	$14,345.18
Richard Colletti	Burlington, VT	Pediatric Gastroenterology	$14,212.91
James Markowitz	New Hyde Park, NY	Pediatric Gastroenterology	$14,009.74
Harland Winter	Boston, MA	Pediatric Gastroenterology	$13,970.52
Robert Baldassano	Philadelphia, PA	Pediatric Gastroenterology	$13,857.27
Benjamin Gold	Atlanta, GA	Pediatric Gastroenterology	$12,400.21
Subramaniam Kugathasan	Atlanta, GA	Pediatric Gastroenterology	$11,600.00
Marla Dubinsky	New York, NY		$11,500.00
Adam Cheifetz	Boston, MA	Gastroenterology (Internal Medicine)	$6,260.00

Prescribed Remicade?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.